The results revealed that ABT-199 exhibits potent activity against Bcl-2-dependent hematologic carcinoma and has a significant inhibitory effect on ALL cells with high Bcl-2 expression. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.